Company Profile

APT Therapeutics Inc (AKA: Advanced Protein Technologies Inc.)
Profile last edited on: 12/30/2019      CAGE: 4CDR9      UEI: KCGRRQA5CKR4

Business Identifier: Knowledge-based, computer-aided drug discovery engine: greatly accelerates drug development cycles
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

4041 Forest Park Avenue
Saint Louis, MO 63108
   (314) 800-4742
Location: Single
Congr. District: 01
County: St. Louis city

Public Profile

Initially dba sAdvanced Protein Technologies Inc., in 2002 the firm was renamed APT Therapeutics. The organizing principle of the firm has been the deelopment of powerful knowledge-based, computer-aided drug discovery engine to enable speed-up of drug development cycles. Genomics having become a primary driving force of the drug discovery process, APT's protein informatics technology can precisely identifying the correct therapeutic proteins and drug targets. As therapeutic protein candidates are identified, the properties of the proteins can be enhanced to increase the probability of clinical success. Then, APT's protein cheminformatics provides a powerful computational solution for developing and optimizing small molecule drug leads. APT Therapeutics is leveraging its platforms in protein informatics, protein cheminformatics, and protein engineering to develop optimized human apyrases as antiplatelet therapies for acute myocardial infarction, stroke, and transplantation complications. The business strategy is to out-license and/or co-develop the drug candidates with pharma partners. U

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2023 2 NIH $2,719,541
Project Title: Immunomodulatory Therapy for Neuropathic Pain
2021 1 NIH $259,576
Project Title: Peripherally Acting Analgesic for Osteoarthritis Pain
2020 1 NIH $300,000
Project Title: Anti-Inflammatory and Anti-Diabetic Therapy for Metabolic Syndrome
2019 2 NIH $1,902,274
Project Title: Antithrombotic Therapy with No Bleeding Risk for Pci
2019 1 NIH $300,000
Project Title: Synergistic Efficacy of an Interleukin 2 Analog and Antitumor Antigen Antibody

Key People / Management

  Ridong Chen -- Founder and CEO

  Brian L Clevinger -- Managing Director, Prolog Ventures

  Eric Gulve -- President of BioGenerator

  Soonseog Jeong -- Co-Founder

  Eric Leire -- former President